{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-09-11&AnsweringBody.=Department+of+Health&max-questionFirstAnswered.=2015-09-16T15%3A15%3A57.573Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-date=2015-09-11&AnsweringBody.=Department+of+Health&max-questionFirstAnswered.=2015-09-16T15%3A15%3A57.573Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-09-11&AnsweringBody.=Department+of+Health&_metadata=all&max-questionFirstAnswered.=2015-09-16T15%3A15%3A57.573Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-date=2015-09-11&AnsweringBody.=Department+of+Health&max-questionFirstAnswered.=2015-09-16T15%3A15%3A57.573Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-09-11&AnsweringBody.=Department+of+Health&max-questionFirstAnswered.=2015-09-16T15%3A15%3A57.573Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-date=2015-09-11&AnsweringBody.=Department+of+Health&max-questionFirstAnswered.=2015-09-16T15%3A15%3A57.573Z", "items" : [{"_about" : "http://data.parliament.uk/resources/418450", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418450/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence assesses significant new drugs and treatments, including those for the treatment of dementia, through its technology appraisal programme. Technology appraisals are conducted in accordance with NICE\u2019s <em>Guide to the methods of technology appraisal 2013<\/em> which is available at:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"http://www.nice.org.uk/article/pmg9/chapter/Foreword\" target=\"_blank\">www.nice.org.uk/article/pmg9/chapter/Foreword<\/a><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T15:15:57.573Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Dementia"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what criteria NICE has set for new dementia treatments to be recommended for provision by the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "10022"}
    , {"_about" : "http://data.parliament.uk/resources/418458", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418458/answer", "answerText" : {"_value" : "<p>The Government fully appreciates the impact that sight loss can have on a person\u2019s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
        }
        , "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
        , "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "9977"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T12:01:58.77Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Ophthalmic Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what recent assessment he has made of the effect of eye clinic liaison officers on improving patient health and social care; and what progress he has made on increasing the provision of such officers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
      }
      , "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
      ], "uin" : "9980"}
    , {"_about" : "http://data.parliament.uk/resources/418459", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418459/answer", "answerText" : {"_value" : "<p>The Government fully appreciates the impact that sight loss can have on a person\u2019s life and the importance of information being available for those newly diagnosed with sight loss, including signposting patients to appropriate support and rehabilitation services.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Eye clinics and their staffing, including eye clinic liaison officers, are commissioned and funded by individual clinical commissioning groups on the basis of local assessments of need.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
        }
        , "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
        , "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "9980"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T12:01:58.707Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Ophthalmic Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what funding his Department provides for eye clinic liaison officers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
      }
      , "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
      ], "uin" : "9977"}
    , {"_about" : "http://data.parliament.uk/resources/418462", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418462/answer", "answerText" : {"_value" : "<p>No such assessment has been made, however we know that there are links between mental ill health and social factors like isolation and family breakdown and that men in certain age-groups are more likely to present with suicidal behaviour. Suicide continues to be more than three times as common in males than in females, 13.8 per 100,000 for males in 2011-13, compared to 4.0 for females.<\/p><p> <\/p><p><em> <\/em><\/p><p> <\/p><p><em>Preventing suicide in England: A cross-government outcomes strategy to save lives<\/em>, published in 2012, identified a number of high risk groups who are priorities for prevention young and middle-aged men. The strategy recognises that factors associated with suicide in men include family and relationship problems including marital breakup and social isolation. The strategy recognises that those who work with men in different settings, especially primary care, need to be particularly alert to the signs of suicidal behaviour.<\/p><p> <\/p><p> <\/p><p> <\/p><p>A review by the Samaritans, <em>Men Suicide and Society<\/em>, published in 2012, also highlighted that middle-aged men in certain socioeconomic groups are at particularly high risk of suicide. It pointed to evidence that suicidal behaviour results from the interaction of complex factors, including a lack of close social and family relationships, personal crises such as divorce, as well as a general \u2018dip\u2019 in subjective wellbeing among people in their mid-years, compared to both younger and older people. The report also found that relationship breakdown is more likely to lead men, rather than women, to suicide and was published in February 2015.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The Government\u2019s first annual report on the suicide prevention strategy was published on 17 January 2014. It highlighted a new agreement designed to promote greater sharing of information with friends and family of people at risk of suicide. The second annual report into suicide prevention was written for people working in local services.<\/p><p> <\/p><p> <\/p><p> <\/p><p>In January 2015, this Government called for every part of the National Health Service to commit to a 'zero suicide' ambition to dramatically reduce suicides. This goes beyond health service boundaries into the whole community, bringing in the police, education, housing, debt support services and so on.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
        }
        , "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
        , "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T12:07:20.807Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Suicide: Males"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect of family separation on male suicide rates.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/523", "label" : {"_value" : "Biography information for Mr Nicholas Brown"}
      }
      , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne East"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Nicholas Brown"}
      ], "uin" : "9993"}
    , {"_about" : "http://data.parliament.uk/resources/418463", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418463/answer", "answerText" : {"_value" : "<p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.<\/p><p> <\/p><p> <\/p><p> <\/p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found by viewing the specialised dermatology service specification at the following link:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf\" target=\"_blank\">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf<\/a><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "10011"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T11:46:53.647Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Hidradenitis Suppurativa"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps NHS England takes to assess the health and social care needs of patients with hidradenitis suppurativa; and what assessment he has made of the ability of the NHS to deliver efficient diagnosis and access to specialist care for such patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "10010"}
    , {"_about" : "http://data.parliament.uk/resources/418464", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/418464/answer", "answerText" : {"_value" : "<p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.<\/p><p> <\/p><p> <\/p><p> <\/p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.<\/p><p> <\/p><p> <\/p><p> <\/p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient\u2019s needs. More information can be found by viewing the specialised dermatology service specification at the following link:<\/p><p> <\/p><p> <\/p><p> <\/p><p><a href=\"http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf\" target=\"_blank\">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf<\/a><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2015-09-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "10010"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2015-09-16T11:46:53.73Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-09-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Hidradenitis Suppurativa"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what progress has been made by NHS England on the production of a commissioning policy for treatments associated with hidradenitis suppurativa; what the proposed scope of that policy is; and when he expects that policy to have been fully developed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "10011"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 6, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}